Brief: Rovi Sees 2030 CDMO Revenue At About 700 Mln Euros
25/03/2025 07:11
March 25 (Reuters) - Laboratorios Farmaceuticos ROVI SA ROVI.MC: SEES 2030 OPERATING REVENUE 1.5X - 1.8X VERSUS 2024 SEES 2030 CDMO REVENUE AT AROUND 700 MILLION EUROS (+2X VERSUS 2024) SEES 2030 TARGETED SPECIALTY PHARMA REVENUE WITH LOW SINGLE DIGIT GROWTH VERSUS 2024 SEES 2030 EBITDA PRE-RESEARCH AND DEVELOPMENT AT 2.5X - 2-8X VERSUS 2024 SEES ANNUAL AVERAGE RESEARCH AND DEVELOPMENT EXPENSES 2025-2030 BETWEEN 40 AND 60 MILLION EUROS Source text: ID:nCNM3g0Jk Further company coverage: ROVI.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))